Trial reportScientific reports2025
Impact of a self management mobile application on quality of life and limb circumference in women with breast cancer related lymphedema.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer-related lymphedema (BCRL) adversely affects the daily performance and quality of life (QoL) in affected patients. This study aimed to determine the Impact of a self-management mobile application on quality of life and limb circumference in women with BCRL. This randomized clinical trial was conducted on 180 patients with BCRL in Shiraz, Iran, from May 2023 to January 2024. The participants were randomly assigned to the intervention (n = 90) and control (n = 90) groups. The control group received the normal treatments at the lymph clinic. In addition to the usual clinic treatments, the intervention group had access to a mobile application for 3 months. The primary outcomes were QoL, assessed using the Lymphedema Life Impact Scale (LLIS), and the difference in arm circumference, measured using a standard tape. After the intervention, the mean (SD) LLIS score in the intervention group was 29.1 (10.7), which was significantly lower than the control group with 39.3 (15.5). This difference was statistically significant (p < 0.001), indicating a substantial improvement in QoL in the intervention group compared to the control group. Additionally, the intervention group showed a lower mean (SD) arm circumference difference of 2.18 (1.4) compared to the control group with 3.78 (2.6). This result also was statistically significant (p < 0.001). Therefore, we recommend using the application to support self-management among women with BCRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.